临床阶段免疫肿瘤疗法公司Imugene正筹备一项融资，并将发布其备受期待的新临床数据，力图在股价暴跌近80%的一年中重燃市场信心。

Leslie Chong is chief executive of Imugene. Paul Jeffers

三位知情人士透露，Imugene的承销商Bell Potter和E&P Financial已于上周末启动对基金经理的“跨墙推介”（wall-crossing）流程。这些人士要求匿名，且Bell Potter、E&P及Imugene方面均未对置评请求作出回应。

据称，Bell Potter告诉基金经理，Imugene本次计划筹资约3500万澳元。融资的同时，公司还将公布其异体CAR-T细胞疗法azer-cel的最新临床数据，其中包括多个完全缓解（CR）和部分缓解（PR）的治疗案例。

此次融资距离Imugene上一次募资已过去两年。彼时，该公司因收购Precision Biosciences的azer-cel许可权，进行了一次总额为6000万澳元的现金融资，分为定向增发与股票购买计划（SPP），发行价为每股8.4澳分。

Imugene无疑希望此次融资能复制本月早些时候Amplia Therapeutics的市场表现——该生物科技公司在宣布胰腺癌试验中取得两个完全缓解结果后，其股价飙升近500%。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.